Pharming Group N.V annual operating income
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Operating Income Growth & History (PHAR)
Pharming Group N.V's operating income was $25.8M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.8M | $34.5M | — |
| 2024 | 2024-12-31 | −$8.6M | −$3.2M | — |
| 2023 | 2023-12-31 | −$5.4M | −$23.6M | — |
| 2022 | 2022-12-31 | $18.2M | $4.7M | +34.45% |
| 2021 | 2021-12-31 | $13.6M | −$62.7M | −82.22% |
| 2020 | 2020-12-31 | $76.3M | $8.0M | +11.74% |
| 2019 | 2019-12-31 | $68.2M | — | — |
Pharming Group N.V quarterly operating income
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$111,000 | −$9.1M | — |
| Q1 2026 | 2026-03-31 | −$5.3M | — | — |
| Q4 2025 | 2025-12-31 | $2.0M | — | — |
| Q3 2025 | 2025-09-30 | $15.8M | — | — |
| Q2 2025 | 2025-06-30 | $9.0M | — | — |
Pharming Group N.V operating income trends
Over the last five fiscal years, Pharming Group N.V's operating income decreased from $76.3M to $25.8M, a change of −$50.4M. The latest reported quarter, Q2 2026, shows −$111,000.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...